Yaping Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yaping Zhang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Wenyu Shi
Department of Oncology, Affiliated Hospital of Nantong University, Nantong, China
15 shared publications Qingfeng Xue
Department of Oncology Affiliated Hospital of Nantong University Nantong China
6 shared publicationsHong Zhou
Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China
5 shared publicationsQingxiu Dang
Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China
5 shared publicationsJing He
Department of Oncology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu, China; Nantong University Medical School, 19, Qixiu Road, Nantong 226001, Jiangsu, China; Department of Clinical Biobank & Institute of Oncology, Nantong University Affiliated Hospital, Nantong 226001, Jiangsu, China
3 shared publicationsJuan Liu
Department of Oncology, Affiliated Hospital of Nantong University, Nantong, China
3 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Management of diffuse large B‑cell lymphoma in older adults: current strategies and emerging directions
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma in older adults. Treatment in this population remains challenging due to heightened genetic heterogeneity and reduced physiological reserve, which increase susceptibility to both treatment-related toxicity and the risk of undertreatment. Comprehensive geriatric assessment is essential to categorize patients as fit, unfit, or frail, enabling individualized therapeutic strategies. Fit patients benefit from standard R-CHOP or Pola-R-CHP regimens, while unfit patients are suitable for dose-reduced regimens. Anthracycline-containing therapy is recommended when feasible; alternatives such as etoposide or gemcitabine may be used when anthracyclines are contraindicated. Frail patients lack standardized treatment protocols, presenting a significant clinical dilemma; however, advances in geriatric assessment tools and novel therapies are expected to shift the management paradigms from purely palliative care to curative‑intent strategies. Current geriatric assessment tools have limitations, and the distinction between unfit and frail remains fluid. Dynamic fitness assessment and pre-phase treatment strategies may enable some patients to “improve” to a higher fitness level. Emerging evidence supports the efficacy of novel targeted agents, including small-molecule inhibitors, bispecific antibodies, and antibody-drug conjugates, which are reshaping first-line treatment paradigms. Nevertheless, their implementation in community settings faces substantial practical barriers, such as the need for cytokine release syndrome monitoring, caregiver burden, financial toxicity, and adherence challenges. This review provides a comprehensive overview of current strategies and emerging directions for managing older adults with DLBCL.
- 25 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessManagement of diffuse large B‑cell lymphoma in older adults: current strategies and emerging directions
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma in older adults. Treatment in this population remains challenging due to heightened genetic heterogeneity and reduced physiological reserve, which increase susceptibility to both treatment-related toxicity and the risk of undertreatment. Comprehensive geriatric assessment is essential to categorize patients as fit, unfit, or frail, enabling individualized therapeutic strategies. Fit patients benefit from standard R-CHOP or Pola-R-CHP regimens, while unfit patients are suitable for dose-reduced regimens. Anthracycline-containing therapy is recommended when feasible; alternatives such as etoposide or gemcitabine may be used when anthracyclines are contraindicated. Frail patients lack standardized treatment protocols, presenting a significant clinical dilemma; however, advances in geriatric assessment tools and novel therapies are expected to shift the management paradigms from purely palliative care to curative‑intent strategies. Current geriatric assessment tools have limitations, and the distinction between unfit and frail remains fluid. Dynamic fitness assessment and pre-phase treatment strategies may enable some patients to “improve” to a higher fitness level. Emerging evidence supports the efficacy of novel targeted agents, including small-molecule inhibitors, bispecific antibodies, and antibody-drug conjugates, which are reshaping first-line treatment paradigms. Nevertheless, their implementation in community settings faces substantial practical barriers, such as the need for cytokine release syndrome monitoring, caregiver burden, financial toxicity, and adherence challenges. This review provides a comprehensive overview of current strategies and emerging directions for managing older adults with DLBCL.
- Open Access
- 3 September 2025
- Published by Wiley in Cancer Science
- Vol. 116 (11) , 2986-2999
Synergistic Efficacy of Chidamide and LB100 in Sézary Syndrome via TNC Downregulation and PI3K / AKT / mTOR Dephosphorylation
Primary cutaneous T‐cell lymphoma (CTCL) manifests as a distinct variant of T‐cell non‐Hodgkin's lymphoma, predominantly impacting skin tissues and constituting approximately 75%–80% of cutaneous lymphoma cases, exhibiting diverse clinical presentations. Sezary syndrome (SS) is a rare subtype of CTCL. The therapeutic approach of SS frequently incorporates multiple chemotherapeutic compounds, encompassing specific histone deacetylase inhibitor agents. Nevertheless, similar to numerous chemotherapeutic protocols, existing monotherapy approaches for SS encounter limitations regarding sustained therapeutic outcomes and optimal effectiveness. This investigation seeks to examine the therapeutic impact and molecular pathways of combining Chidamide with LB100 in the treatment of SS. The synergistic effects of Chidamide and LB100 were evaluated in SS cell lines (Hut78 and H9) using the Cell Counting Kit‐8, Chou‐Talalay combination index, colony formation assays, and mouse xenograft models. Apoptosis was examined by Annexin V‐APC/PI staining. The molecular mechanisms were explored through transcriptome sequencing, Western blotting, immunohistochemistry, and Lentivirus transfection. Chidamide and LB100 demonstrated synergistic antitumor activity in SS cell lines (Hut78 and H9) in vitro, with a combination index (CI) < 1. This synergy was also confirmed in Hut78 xenograft mice. Mechanistically, the two agents downregulated Tenascin C (TNC) and caused dephosphorylation of the PI3K/AKT/mTOR signaling cascade. This study also preliminarily validated the effect of the combination of the two drugs on other subtypes of CTCL. Overall, these findings provide potential new therapeutic strategies for CTCL (especially SS), although further clinical evaluation is required to validate these results.
- 3 September 2025
- Published by Wiley in Cancer Science
- Vol. 116 (11) , 2986-2999
Open AccessSynergistic Efficacy of Chidamide and LB100 in Sézary Syndrome via TNC Downregulation and PI3K / AKT / mTOR Dephosphorylation
Primary cutaneous T‐cell lymphoma (CTCL) manifests as a distinct variant of T‐cell non‐Hodgkin's lymphoma, predominantly impacting skin tissues and constituting approximately 75%–80% of cutaneous lymphoma cases, exhibiting diverse clinical presentations. Sezary syndrome (SS) is a rare subtype of CTCL. The therapeutic approach of SS frequently incorporates multiple chemotherapeutic compounds, encompassing specific histone deacetylase inhibitor agents. Nevertheless, similar to numerous chemotherapeutic protocols, existing monotherapy approaches for SS encounter limitations regarding sustained therapeutic outcomes and optimal effectiveness. This investigation seeks to examine the therapeutic impact and molecular pathways of combining Chidamide with LB100 in the treatment of SS. The synergistic effects of Chidamide and LB100 were evaluated in SS cell lines (Hut78 and H9) using the Cell Counting Kit‐8, Chou‐Talalay combination index, colony formation assays, and mouse xenograft models. Apoptosis was examined by Annexin V‐APC/PI staining. The molecular mechanisms were explored through transcriptome sequencing, Western blotting, immunohistochemistry, and Lentivirus transfection. Chidamide and LB100 demonstrated synergistic antitumor activity in SS cell lines (Hut78 and H9) in vitro, with a combination index (CI) < 1. This synergy was also confirmed in Hut78 xenograft mice. Mechanistically, the two agents downregulated Tenascin C (TNC) and caused dephosphorylation of the PI3K/AKT/mTOR signaling cascade. This study also preliminarily validated the effect of the combination of the two drugs on other subtypes of CTCL. Overall, these findings provide potential new therapeutic strategies for CTCL (especially SS), although further clinical evaluation is required to validate these results.
- Open Access
- 29 October 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt A) , 111125
Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway
- 29 October 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt A) , 111125
Open AccessSingle-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway
- Open Access
- 17 April 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics
Chronic active Epstein-Barr virus disease (CAEBV) is a systemic lymphoproliferative disorder that is closely linked to Epstein-Barr virus (EBV) infection. The clinical course and severity of CAEBV can vary, and in some cases, it can progress to overt lymphoma, which is characterized by extranodal natural killer/T-cell lymphoma (ENKTL) and has a poor clinical outcome. Although anti-programmed cell death protein-1 (PD-1) therapy has shown effectiveness in some patients with EBV-associated disease, it has been less successful in others, and the exact mechanism of action of PD-1 inhibitor therapy in these diseases remains unclear. In this report, we describe a patient who was diagnosed with ENKTL secondary to CAEBV and experienced rapid disease progression accompanied by hyperinflammation after receiving PD-1 inhibitor therapy. Single-cell RNA sequencing revealed a significant increase in the patient’s lymphocyte count, especially in natural killer cells, with increased activity following PD-1 inhibitor therapy. This case raises questions about the efficacy and safety of PD-1 inhibitor therapy in patients with EBV-associated diseases.
- 17 April 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
Open AccessCase report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics
Chronic active Epstein-Barr virus disease (CAEBV) is a systemic lymphoproliferative disorder that is closely linked to Epstein-Barr virus (EBV) infection. The clinical course and severity of CAEBV can vary, and in some cases, it can progress to overt lymphoma, which is characterized by extranodal natural killer/T-cell lymphoma (ENKTL) and has a poor clinical outcome. Although anti-programmed cell death protein-1 (PD-1) therapy has shown effectiveness in some patients with EBV-associated disease, it has been less successful in others, and the exact mechanism of action of PD-1 inhibitor therapy in these diseases remains unclear. In this report, we describe a patient who was diagnosed with ENKTL secondary to CAEBV and experienced rapid disease progression accompanied by hyperinflammation after receiving PD-1 inhibitor therapy. Single-cell RNA sequencing revealed a significant increase in the patient’s lymphocyte count, especially in natural killer cells, with increased activity following PD-1 inhibitor therapy. This case raises questions about the efficacy and safety of PD-1 inhibitor therapy in patients with EBV-associated diseases.
- Open Access
A Rare B-Myeloid Conversion of Follicular Lymphoma into Clonally Related Acute Myeloid Leukemia: A Case Report
Follicular lymphoma (FL) is a highly prevalent indolent lymphoma, and the risk of histological transformation is approximately 2–3% per year. Transformation of FL generally occurs in the same lineage (B cell lineage). Another rare form of disease progression is the transformation of neoplastic B-cells to another cell lineage such as acute myeloid leukemia (AML). The low incidence of B-myeloid transformation associated with poor prognosis hinders the establishment of model systems to identify molecular mechanisms. A 64-year-old woman was diagnosed with FL and achieved a satisfactory response after six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Approximately one month after treatment terminated, the disease progressed to AML with an increased white blood cell count and abnormal coagulation. Interestingly, nucleotide sequence analysis of the genomic region encoding the immunoglobulin heavy-chain variable domain showed the possibility of homologous transformation from lymphoma to leukemia cells. Although the patient experienced transient improvement after undergoing treatment with one cycle of idarubicin and cytarabine combined with etoposide, she relapsed and died 8 days after venetoclax salvage therapy. Patient with B-myeloid transformation was associated with an aggressive clinical course and poor prognosis. Conventional strategies for treating histologically transformed AML were ineffective. However, treatment with a Bcl-2 inhibitor could serve as an option. Here we review the literature relevant to this rare histological transformation of FL.
Open AccessA Rare B-Myeloid Conversion of Follicular Lymphoma into Clonally Related Acute Myeloid Leukemia: A Case Report
Follicular lymphoma (FL) is a highly prevalent indolent lymphoma, and the risk of histological transformation is approximately 2–3% per year. Transformation of FL generally occurs in the same lineage (B cell lineage). Another rare form of disease progression is the transformation of neoplastic B-cells to another cell lineage such as acute myeloid leukemia (AML). The low incidence of B-myeloid transformation associated with poor prognosis hinders the establishment of model systems to identify molecular mechanisms. A 64-year-old woman was diagnosed with FL and achieved a satisfactory response after six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Approximately one month after treatment terminated, the disease progressed to AML with an increased white blood cell count and abnormal coagulation. Interestingly, nucleotide sequence analysis of the genomic region encoding the immunoglobulin heavy-chain variable domain showed the possibility of homologous transformation from lymphoma to leukemia cells. Although the patient experienced transient improvement after undergoing treatment with one cycle of idarubicin and cytarabine combined with etoposide, she relapsed and died 8 days after venetoclax salvage therapy. Patient with B-myeloid transformation was associated with an aggressive clinical course and poor prognosis. Conventional strategies for treating histologically transformed AML were ineffective. However, treatment with a Bcl-2 inhibitor could serve as an option. Here we review the literature relevant to this rare histological transformation of FL.
- Open Access
- 8 February 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 815654
Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase expressed at early stages of normal development and in various cancers including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), in which it is the main therapeutic target. ALK tyrosine kinase inhibitors (ALK TKIs) have greatly improved the prognosis of ALK+ALCL patients, but the emergence of drug resistance is inevitable and limits the applicability of these drugs. Although various mechanisms of resistance have been elucidated, the problem persists and there have been relatively few relevant clinical studies. This review describes research progress on ALK+ ALCL including the application and development of new therapies, especially in relation to drug resistance. We also propose potential treatment strategies based on current knowledge to inform the design of future clinical trials.
- 8 February 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 815654
Open AccessHolistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase expressed at early stages of normal development and in various cancers including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), in which it is the main therapeutic target. ALK tyrosine kinase inhibitors (ALK TKIs) have greatly improved the prognosis of ALK+ALCL patients, but the emergence of drug resistance is inevitable and limits the applicability of these drugs. Although various mechanisms of resistance have been elucidated, the problem persists and there have been relatively few relevant clinical studies. This review describes research progress on ALK+ ALCL including the application and development of new therapies, especially in relation to drug resistance. We also propose potential treatment strategies based on current knowledge to inform the design of future clinical trials.
- 27 September 2021
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 22 (10-12) , 537-543
Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review
Follicular lymphoma (FL) accounts for approximately 35% of all non-Hodgkin lymphomas and can progress to diffuse large B cell lymphoma (DLBCL) at a rate of 2% per year. Here, we present a 56-year-old female patient who was diagnosed with grade 3a FL. Further pathological investigation revealed that the lymphoma had transformed into DLBCL following six courses of R-CHOP regimen, and further disease progression was observed after two courses of R2-GemOx. We ultimately failed to collect hematopoietic stem cells after two courses of R2-ICE. CD-22 CAR-T cell therapy salvaged the patient; however, a new soft tissue mass of 4.8 × 4.1 cm rapidly emerged in the patient’s right lung. Following the observation of strong tissue staining of PD-L1 (90%), the patient was administered PD-1 inhibitor and 26 Gy of radiotherapy and has maintained progression-free survival at more than 15 months of follow-up. Transformed FL with strong PD-L1 expression showed a poor response to standard immunochemotherapy. Our findings support the potential benefit of PD-1 inhibitor and combination therapies in this type of transformed FL.
- 27 September 2021
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 22 (10-12) , 537-543
Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review
Follicular lymphoma (FL) accounts for approximately 35% of all non-Hodgkin lymphomas and can progress to diffuse large B cell lymphoma (DLBCL) at a rate of 2% per year. Here, we present a 56-year-old female patient who was diagnosed with grade 3a FL. Further pathological investigation revealed that the lymphoma had transformed into DLBCL following six courses of R-CHOP regimen, and further disease progression was observed after two courses of R2-GemOx. We ultimately failed to collect hematopoietic stem cells after two courses of R2-ICE. CD-22 CAR-T cell therapy salvaged the patient; however, a new soft tissue mass of 4.8 × 4.1 cm rapidly emerged in the patient’s right lung. Following the observation of strong tissue staining of PD-L1 (90%), the patient was administered PD-1 inhibitor and 26 Gy of radiotherapy and has maintained progression-free survival at more than 15 months of follow-up. Transformed FL with strong PD-L1 expression showed a poor response to standard immunochemotherapy. Our findings support the potential benefit of PD-1 inhibitor and combination therapies in this type of transformed FL.
- Open Access
- 1 April 2021
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 14, 2489-2495
Promising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report
Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) complicated with angioimmunoblastic T-cell lymphoma (AITL) is extremely rare and typically shows an aggressive clinical course and unsatisfactory prognosis. Here, we describe the case of a 77-year-old man who was referred to the hospital because of repeated fever, night sweats, and weight loss. He was finally diagnosed with a discordant lymphoma consisting of AITL and DLBCL, with significantly different maximum standardized uptake values on positron emission tomography/computed tomography. Based on his complex illness and poor performance status, the patient received six cycles of lenalidomide combined with R-miniCHOP regimen and achieved complete remission with tolerable and controlled toxicity. He subsequently received lenalidomide maintenance therapy and achieved sustained remission. We consider the possible causes of this discordance involved AITL and EBV-positive DLBCL, and the possible mechanism of lenalidomide action in both T-cell and B-cell non-Hodgkin lymphomas. Lenalidomide-combination therapy may be a preferable choice in patients with an EBV-associated discordant lymphoma.
- 1 April 2021
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 14, 2489-2495
Open AccessPromising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report
Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) complicated with angioimmunoblastic T-cell lymphoma (AITL) is extremely rare and typically shows an aggressive clinical course and unsatisfactory prognosis. Here, we describe the case of a 77-year-old man who was referred to the hospital because of repeated fever, night sweats, and weight loss. He was finally diagnosed with a discordant lymphoma consisting of AITL and DLBCL, with significantly different maximum standardized uptake values on positron emission tomography/computed tomography. Based on his complex illness and poor performance status, the patient received six cycles of lenalidomide combined with R-miniCHOP regimen and achieved complete remission with tolerable and controlled toxicity. He subsequently received lenalidomide maintenance therapy and achieved sustained remission. We consider the possible causes of this discordance involved AITL and EBV-positive DLBCL, and the possible mechanism of lenalidomide action in both T-cell and B-cell non-Hodgkin lymphomas. Lenalidomide-combination therapy may be a preferable choice in patients with an EBV-associated discordant lymphoma.